fbpx

Day

december 4, 2017
Funds will support Phase 2 study of Reltecimod for Acute Kidney Injury; Phase 3 study of Reltecimod for Necrotizing Soft Tissue Infections (“flesh eating bacteria”) ongoing Ness Ziona, Israel and Chapel Hill, NC – December 4, 2017 – Atox Bio, a clinical stage biotechnology company developing novel therapies for critically ill patients, today announced that...

Nyheder

Lundbeckfonden
Hjernesygdomme koster samfundet mindst 39 mia. kroner
18. november 2020
Danske forskere leverer beviset: Kejsersnit kan lede til astma og allergi
12. november 2020
En helt ny slags ’antabus’ – men mod kokainmisbrug
10. november 2020

Lundbeckfonden

Lundbeckfonden Ventures

Lundbeckfonden Emerge